Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Surface Oncology stock | $7.7

Learn how to easily invest in Surface Oncology stock.

Surface Oncology Inc is a biotechnology business based in the US. Surface Oncology shares (SURF) are listed on the NASDAQ and all prices are listed in US Dollars. Surface Oncology employs 51 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Surface Oncology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SURF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Surface Oncology stock price (NASDAQ: SURF)

Use our graph to track the performance of SURF stocks over time.

Surface Oncology shares at a glance

Information last updated 2021-10-09.
Latest market close$7.70
52-week range$5.06 - $14.40
50-day moving average $6.80
200-day moving average $7.12
Wall St. target price$16.40
PE ratio 19.3267
Dividend yield N/A (0%)
Earnings per share (TTM) $0.40

Buy Surface Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Surface Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Surface Oncology price performance over time

Historical closes compared with the close of $7.7 from 2021-10-15

1 week (2021-10-08) -0.65%
1 month (2021-09-16) 28.12%
3 months (2021-07-16) 16.84%
6 months (2021-04-16) 13.40%
1 year (2020-10-16) -18.26%
2 years (2019-10-16) 474.63%
3 years (2018-10-16) 8.39
5 years (2016-10-12) N/A

Is Surface Oncology under- or over-valued?

Valuing Surface Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surface Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Surface Oncology's P/E ratio

Surface Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Surface Oncology shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Surface Oncology's EBITDA

Surface Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.3 million.

The EBITDA is a measure of a Surface Oncology's overall financial performance and is widely used to measure a its profitability.

Surface Oncology financials

Revenue TTM $89.7 million
Operating margin TTM 24.15%
Gross profit TTM $86.3 million
Return on assets TTM 7.52%
Return on equity TTM 13.86%
Profit margin 18.99%
Book value $3.34
Market capitalisation $352.3 million

TTM: trailing 12 months

Shorting Surface Oncology shares

There are currently 3.6 million Surface Oncology shares held short by investors – that's known as Surface Oncology's "short interest". This figure is 1.8% up from 3.5 million last month.

There are a few different ways that this level of interest in shorting Surface Oncology shares can be evaluated.

Surface Oncology's "short interest ratio" (SIR)

Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology shares currently shorted divided by the average quantity of Surface Oncology shares traded daily (recently around 434961.76115802). Surface Oncology's SIR currently stands at 8.29. In other words for every 100,000 Surface Oncology shares traded daily on the market, roughly 8290 shares are currently held short.

However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology shares, or, against the total number of tradable Surface Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Surface Oncology shares in existence, roughly 80 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Surface Oncology shares, roughly 104 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Surface Oncology.

Find out more about how you can short Surface Oncology stock.

Surface Oncology share dividends

We're not expecting Surface Oncology to pay a dividend over the next 12 months.

Surface Oncology share price volatility

Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $5.055 up to $14.4. A popular way to gauge a stock's volatility is its "beta".

SURF.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.6545. This would suggest that Surface Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Surface Oncology overview

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc.

Frequently asked questions

What percentage of Surface Oncology is owned by insiders or institutions?
Currently 9.355% of Surface Oncology shares are held by insiders and 59.736% by institutions.
How many people work for Surface Oncology?
Latest data suggests 51 work at Surface Oncology.
When does the fiscal year end for Surface Oncology?
Surface Oncology's fiscal year ends in December.
Where is Surface Oncology based?
Surface Oncology's address is: 50 Hampshire Street, Cambridge, MA, United States, 02139
What is Surface Oncology's ISIN number?
Surface Oncology's international securities identification number is: US86877M2098
What is Surface Oncology's CUSIP number?
Surface Oncology's Committee on Uniform Securities Identification Procedures number is: 86877M209

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site